Abraham Hartzema

Abraham Hartzema Pharm.D., MSPH, Ph.D., FISPE

Emeritus Professor and Perry A. Foote Eminent Scholar Chair

Department: Pharmaceutical Outcomes & Policy
Business Email: hartzema@ufl.edu

About Abraham Hartzema

Abraham G. Hartzema is Professor and Eminent Scholar at the University of Florida in the Department of Pharmaceutical Outcomes & Policy. He is the Perry A. Foote Chair in Health Outcomes Research, and Professor in Epidemiology and Biostatistics in the College of Public Health and the College of Medicine. In the year 2007, he was awarded the University of Florida Foundation Research award.

Dr. Hartzema has widely published on various aspects of prescription drug safety, including several books on Pharmacoepidemiology. His last book is entitled “Pharmacoepidemiology and Therapeutic Risk Management” was published by Harvey Whitney Book Publishers. Co-edited with Hugh Tilson (UNC-Chapel Hill) and Arnold Chan (Harvard University) the book reflects the new therapeutic risk management paradigm as implemented by the US FDA.

He has served on the scientific board of the FIP from 1988-1996; and on editorial boards, including Medical Care, Annals of Pharmacotherapy, Clinical Therapeutics, the International Journal of Pharmacy Practice, Pulmonary Circulation and others. In 2003 he was bestowed fellow status in the International Society on Pharmacoepidemiology. He has been the Chair of Data Safety and Monitoring Boards. He has also served on the University of Florida Graduate Council, and grant review panels for AHRQ, FDA, HealthCanada, DSEN, NASA, NIH, and NIHBL. He currently serves on the United States Pharmacopeia: Nomenclature, Safety and Labeling Expert Committee. He was recently appointed as Senior Advisor to the FDA, Center for Devices and Radiological Health.

Dr. Hartzema’s research funded by the Agency for Healthcare Research and Quality, NIH, the FDA, the Florida Office of Rural Health and several pharmaceutical companies. His theoretical interests are in data mining techniques, developing metrics for the benefit/risk ratio of drugs, methods development for active medical product safety surveillance, and bias calibration in observational methods.

Dr. Hartzema was on faculty leave (2008–2009) in the US Food and Drug Administration’s Immediate Office of the Commissioner working on the Congressional mandated Sentinel Initiative. He also served as a Principle Investigator on the Observational Medical Outcomes Partnership (OMOP), a public-private partnership between the US-FDA, the Foundation of the National Institute of Health and PhRMA. He is currently a participant in the research group Observational Health Data Sciences and Informatics (OHDSI) research program.

Research Profile

Health outcomes research with an emphasis on: Pharmacoepidemiology, Active Drug Safety, Surveillance methods development, Therapeutic risk management and Program evaluation

Publications

2017 American Journal Of Health-System Pharmacy : Ajhp : Official Journal Of The American Society Of Health-System Pharmacists
2006 American Journal of Health-System Pharmacy

Grants

September 2013 – August 2014
Comparative Safety of Alternative Articulating Surfaces
AMER FOU FOR PHARM EDU (AFPE) · Principal Investigator
September 2012 – August 2013
AFPE Fellowship
AMER FOU FOR PHARM EDU (AFPE) · Principal Investigator
September 2012 – August 2013
Medication Adherence during Treatment for the Hepatitis
AMER FOU FOR PHARM EDU (AFPE) · Principal Investigator
January 2008 – June 2008
Medicare Rural Hospital Flexibility Program
FL DEPT OF HLTH · Principal Investigator
April 2007 – June 2007
Guidance and Evaluation of Pharmacy Health Information
FL DEPT OF HLTH · Principal Investigator
February 2007 – February 2008
An Evaluation of Resources Consumption in Disease Progre
PFIZER INC · Principal Investigator
November 2006 – February 2007
Resource Use, Costs, and Persistency of Iron Chelation
NOVARTIS PHARMACEUTICALS CORP · Principal Investigator
April 2001 – June 2006
MISCELLANEOUS DONORS
MISCELLANEOUS DONORS · Principal Investigator